Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Director Garen G. Bohlin Sells 28,985 Shares

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Director Garen G. Bohlin sold 28,985 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $32.30, for a total transaction of $936,215.50. Following the completion of the transaction, the director now owns 44,775 shares in the company, valued at approximately $1,446,232.50. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Collegium Pharmaceutical Stock Down 1.7 %

Shares of COLL traded down $0.58 during trading hours on Friday, hitting $33.09. 85,689 shares of the company were exchanged, compared to its average volume of 446,711. The firm’s 50 day moving average is $37.23 and its 200-day moving average is $32.61. The company has a debt-to-equity ratio of 1.98, a quick ratio of 1.14 and a current ratio of 1.21. Collegium Pharmaceutical, Inc. has a 52 week low of $20.83 and a 52 week high of $40.95. The company has a market cap of $1.08 billion, a PE ratio of 14.03 and a beta of 1.06.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.20 by $0.25. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. The firm had revenue of $149.75 million during the quarter, compared to analysts’ expectations of $147.66 million. On average, equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.63 EPS for the current fiscal year.

Analysts Set New Price Targets

COLL has been the subject of several recent research reports. Piper Sandler lowered Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 price objective for the company. in a report on Friday, May 10th. Needham & Company LLC lowered Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a report on Friday, May 10th. Truist Financial boosted their price target on Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, February 26th. Finally, StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 1st. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $39.00.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of COLL. Principal Securities Inc. bought a new stake in Collegium Pharmaceutical during the fourth quarter valued at about $40,000. China Universal Asset Management Co. Ltd. boosted its stake in Collegium Pharmaceutical by 320.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,776 shares of the specialty pharmaceutical company’s stock valued at $116,000 after purchasing an additional 2,877 shares during the period. Assetmark Inc. grew its holdings in Collegium Pharmaceutical by 25.5% in the 4th quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock valued at $168,000 after buying an additional 1,108 shares during the last quarter. Sheaff Brock Investment Advisors LLC acquired a new position in shares of Collegium Pharmaceutical during the first quarter worth approximately $204,000. Finally, Versor Investments LP acquired a new position in shares of Collegium Pharmaceutical during the third quarter worth approximately $207,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.